| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,808 |
| 52
Week Range: |
$0.4435 - $1.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman and CEO |
• – – |
2008-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
68,750 |
335,360 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2008-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
28,022 |
|
- |
|
| Wentworth Kerry |
VP Reg Affairs & Clinical Ops |
• – – |
2008-01-07 |
4 |
D |
$2.15 |
$5,551 |
D/D |
(2,582) |
5,885 |
|
- |
|
| Wentworth Kerry |
VP Reg Affairs & Clinical Ops |
• – – |
2008-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,906 |
8,467 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-09-14 |
4 |
B |
$2.33 |
$116,570 |
D/D |
50,000 |
266,610 |
2.74 |
- |
|
| Hatsopoulos John |
Director |
– • – |
2007-06-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
70,000 |
|
- |
|
| Hatsopoulos John |
Director |
– • – |
2007-06-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,000 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2007-03-22 |
4 |
A |
$1.97 |
$420 |
D/D |
213 |
2,578 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2007-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
2,791 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-03-15 |
4 |
B |
$2.03 |
$20,293 |
D/D |
10,000 |
216,610 |
2.74 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-03-14 |
4 |
B |
$2.01 |
$30,090 |
D/D |
15,000 |
206,610 |
2.74 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-03-13 |
4 |
B |
$2.00 |
$20,001 |
D/D |
10,000 |
191,610 |
2.74 |
- |
|
| Sharp Shalini |
CFO |
• – – |
2007-03-13 |
4 |
B |
$1.97 |
$9,836 |
D/D |
5,000 |
19,579 |
2.74 |
- |
|
| Sharp Shalini |
CFO |
• – – |
2007-03-12 |
4 |
B |
$1.95 |
$9,736 |
D/D |
5,000 |
14,579 |
2.74 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-03-12 |
4 |
B |
$1.91 |
$47,813 |
D/D |
25,000 |
181,610 |
2.74 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-03-09 |
4 |
B |
$1.83 |
$45,740 |
D/D |
25,000 |
156,610 |
2.74 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2007-03-08 |
4 |
B |
$1.82 |
$45,528 |
D/D |
25,000 |
131,610 |
2.74 |
- |
|
| Armen Garo H |
CEO and Chairman of the Board |
• – – |
2007-02-09 |
4 |
B |
$1.93 |
$96,500 |
D/D |
50,000 |
106,610 |
2.74 |
- |
|
| Srivastava Pramod |
Director |
– • – |
2007-02-09 |
4 |
S |
$1.93 |
$96,500 |
D/D |
(50,000) |
1,610 |
|
- |
|
| Afeyan Noubar |
Director |
– • – |
2006-12-14 |
4 |
S |
$1.95 |
$9,759 |
D/D |
(5,000) |
0 |
|
- |
|
| Thornton Peter |
Director |
– • – |
2006-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,188 |
|
- |
|
| Atlee Frank V III |
Director |
– • – |
2006-11-02 |
4 |
S |
$2.15 |
$9,675 |
D/D |
(4,500) |
0 |
|
- |
|
| Klaskin Christine M |
VP, FinanceOfficer |
• – – |
2006-10-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
195 |
|
- |
|
| Klaskin Christine M |
VP, FinanceOfficer |
• – – |
2006-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,291 |
|
- |
|
| Sharp Shalini |
CFOOfficer |
• – – |
2006-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,079 |
|
- |
|
537 Records found
|
|
Page 21 of 22 |
|
|
